GALENA BIOPHARMA, INC. FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders

Edgar Glimpses |


Annual Meeting of Stockholders

The Annual Meeting of stockholders of Galena Biopharma, Inc. ("we," "us," "our" or the "company") was held on June 27, 2014. On April 30, 2014, we filed with the Securities and Exchange Commission our definitive proxy statement relating to the Annual Meeting.

At the Annual Meeting, our stockholders acted upon the following proposals, which are described in detail in our proxy statement: • Proposal 1: To re-elect William L. Ashton, Richard Chin, M.D. and Rudolph Nisi, M.D. as Class I Directors to serve until the 2017 Annual Meeting of stockholders; • Proposal 2: To approve, by non-binding vote, the compensation of our named executive officers as disclosed in our proxy statement; and • Proposal 3: To ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014.

Voting Results

Proposal 1: Mr. Ashton and Drs. Chin and Nisi were re-elected as Class I Directors by the following votes:

"FOR" "WITHHELD" William L. Ashton 15,860,921 2,035,392 Richard Chin, M.D. 14,564,801 3,331,512 Rudolph Nisi, M.D. 14,094,843 3,801,470

In addition, there were 67,415,925 broker non-votes in connection with this proposal.

Proposal 2: This proposal was approved with 12,544,457 votes "FOR," 4,735,686 votes "AGAINST," and 616,170 votes to "ABSTAIN." In addition, there were 67,415,925 broker non-votes in connection with this proposal.

Proposal 3: This proposal was approved with 80,310,876 votes "FOR," 3,873,038 votes "AGAINST," and 1,128,324 votes to "ABSTAIN." There were no broker non-votes in connection with this proposal.


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
TIRTZ Tidelands Royalty Trust B 1.25 -0.13 -9.42 300


Emerging Growth

IBC Advanced Alloys Corp.

IBC Advanced Alloys Corp is engaged in the production and development of specialty alloy products. Its products include copper alloys and berryllium aluminium alloys.

Private Markets


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…